Similar articles

• Repetitive levosimendan in outpatients affected by advanced heart failure: the need for a uniform approach.

  Maiello C, Cacciatore F, Amarelli C, Palmieri V, Golino P. Maiello C, et al. J Cardiovasc Med (Hagerstown). 2021 Feb 1;22(2):149. doi: 10.2459/JCM.0000000000001090. J Cardiovasc Med (Hagerstown). 2021. PMID: 32858638 No abstract available.
• Repeated infusion of levosimendan in outpatients with advanced heart failure: to cure sometimes, to relieve often, and to comfort always.

  Masarone D, Pacileo G. Masarone D, et al. J Cardiovasc Med (Hagerstown). 2021 Feb 1;22(2):150. doi: 10.2459/JCM.0000000000001100. J Cardiovasc Med (Hagerstown). 2021. PMID: 32858644 No abstract available.
• Levosimendan in Advanced Heart Failure: Where Do We Stand?

  Abbate A, Van Tassell BW. Abbate A, et al. J Cardiovasc Pharmacol. 2018 Mar;71(3):127-128. doi: 10.1097/FJC.0000000000000539. J Cardiovasc Pharmacol. 2018. PMID: 28953106 Free PMC article. No abstract available.
• Levosimendan: a novel inotropic agent for treatment of acute, decompensated heart failure.

  Earl GL, Fitzpatrick JT. Earl GL, et al. Ann Pharmacother. 2005 Nov;39(11):1888-96. doi: 10.1345/aph.1G128. Epub 2005 Oct 11. Ann Pharmacother. 2005. PMID: 16219899 Review.
• Repetitive use of levosimendan for treatment of chronic advanced heart failure: clinical evidence, practical considerations, and perspectives: an expert panel consensus.

  Nieminen MS, Altenberger J, Ben-Gal T, Böhmer A, Comin-Colet J, Dickstein K, Edes I, Fedele F, Fonseca C, García-González MJ, Giannakoulas G, Iakobishvili Z, Jääskeläinen P, Karavidas A, Kettner J, Kivikko M, Lund LH, Matskeplishvili ST, Metra M, Morandi F, Oliva F, Parkhomenko A, Parissis J, Pollesello P, Pölzl G, Schwinger RH, Segovia J, Seidel M, Vrtovec B, Wikström G. Nieminen MS, et al. Int J Cardiol. 2014 Jun 15;174(2):360-7. doi: 10.1016/j.ijcard.2014.04.111. Epub 2014 Apr 18. Int J Cardiol. 2014. PMID: 24780540